Compare Merck & Co., Inc. (MRK) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Merck & Co., Inc. trades at $133.82 (market cap $327.94B), while abrdn Physical Palladium Shares ETF trades at $23.95. The key difference: Merck & Co., Inc. pays a 2.56% dividend while abrdn Physical Palladium Shares ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| MRK | PALL | |
|---|---|---|
Market Cap | $327.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $132.93 | $37.18 |
52-Week Low | $77.60 | $19.96 |
Enterprise Value | $374.70B | — |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $133.30, up 2.18% today, with a bullish technical signal and strong institutional buying interest. Recent earnings beats and the acquisition of Terns Pharmaceuticals for $6.7 billion highlight strategic growth in oncology. The stock shows robust cash flow from operations of $16.47 billion in 2025 and a consensus price target of $140.58, indicating potential upside.
Outlook remains positive with analyst consensus at 67.57% buy ratings, though risks include high P/E of 106.34 and net income margin volatility. The acquisition expands Merck's pipeline but integration execution is key. Dividend yield supports income investors, while valuation metrics suggest careful monitoring of earnings growth sustainability.
PALL trades at $24.85, down 1.04% over 24 hours. Technical indicators show a bullish trend with moving averages supporting a buy signal, though the RSI suggests potential overbought conditions. The stock underwent a 1:5 split effective May 18, 2026. Recent financial ratios are unavailable, limiting fundamental assessment. News sentiment highlights palladium's price weakness as a potential buying opportunity amid supply risks and industrial demand.
Outlook: PALL presents a speculative opportunity tied to palladium's recovery, with technical strength but limited fundamental data. Risks include commodity price volatility and macroeconomic factors. Investors should weigh the bullish technicals against the absence of current financial metrics and exposure to precious metal market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
